Inbiose Partners with DuPont Nutrition & Health to Bring a Novel Infant Nutrition Ingredient to Market

Inbiose Dupont partnering

Inbiose and DuPont Nutrition & Health (DuPont) have announced a joint development and licensing agreement for exclusive rights to selected fucosylated human milk oligosaccharides (HMOs), including 2’-fucosyllactose. Our collaboration with DuPont, a world-renown ingredient manufacturer, advances our technology and will accelerate the introduction of our first HMO to improve the health and well-being of infants. HMOs are important targets for Inbiose and the market launch of 2’-fucosyllactose represents a key milestone for the company.

More information.

Probiotics Prebiotics in Pediatrics 2016 -- 28-30 April, 2016 -- Gent Belgium

Probiotics Prebiotics in Pediatrics 2016

Wim Soetaert, chairman of Inbiose, presented an update on Inbiose technology for the mass production of human milk oligosaccharides on the 29th of april at the International symposium on Probiotics and Prebiotics in Pediatrics, 2016.

EFIB -- Brussels, Belgium -- 27-29 October, 2015

EFIB 2015

Inbiose is proud to be one of the exhibitor of 8th European Forum for Industrial Biotechnology and the Biobased Economy where we communicated our latest development for the efficient production of new specialty carbohydrates.

Carbosurf (Horizon 2020) Project: New processes for the fermentative production of glycolipid biosurfactants and sialylated carbohydrates

BBI consortium : logo BBI JU : logo European Union

Inbiose was granted the Horizon 2020 Carbosurf research project.

This program will support our company development aiming at increasing our portfolio of more complex and high added-value specialty carbohydrates. Specifically, the project targets the development of innovative fermentation processes to produce sialylated oligosaccharides, a class of very complex Human Milk Oligosaccharides that find a wide variety of application as neutraceutical, pharmaceutical and cosmetic ingredients. Learn more.

Faseb meeting: Origins and Benefits of Biologically Active Components in Human Milk. July 19-24 2015, Big Sky, Montana, USA

Faseb 2015

Inbiose is proud to be a gold sponsor of this inevitable event focusing on the health benefits of Human milk oligosaccharides. Inbiose presented new developments about large scale production of human milk oligosaccharides. Learn more.

Joint meeting of the SFG (Society for Glycobiology) and JSCR (Japanese society of carbohydrate research- Honolulu, USA - November 16th - 18th, 2014

Joint meeting of the SFG and JSCR

Inbiose presented during the Consortium for Functional Glycomics Workshops in Molecular and Cellular Glycosciences. Learn more.

EFIB - Reims, France - September 30th - October 2nd, 2014

EFIB: logo

Inbiose presented at the 7th European Forum for Industrial Biotechnology and the Biobased Economy.

Knowledge for growth - Ghent, Belgium - May 8th, 2014

Knowledge for growth: logoInbiose was at the Knowledge for growth convention where our new human milk oligosaccharides offer was presented.

Bio - World congress on industrial Biotechnology - Philadelphia, USA - May 12-15th, 2014

Bio: logo Inbiose attended Bio convention in Philadelphia, USA. We presented our company and products during track 4 session 1, Tuesday 13th May (8:30 – 10:00 am)

Have a look at the presentation abstract (page 21): Image pdf_logoInbiose technology: Efficient synthesis of specialty carbohydrates through industrial biotechnology.

IB2Market (FP7) Bringing innovative industrial biotechnology research to the market

IB2Market: logo Inbiose was granted the FP7 IB2Market research project.

This program fits in our company mission: bridging the gap between research and commercialisation of rare carbohydrates.

Share: on LinkedIn